Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa
British Journal of Clinical Pharmacology · 2024-05 · 90 (5) · 1247-1257
DOI: 10.1111/bcp.16009 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 08.02.2024. Verfasst von Rephaim Mpofu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Pyridones, Oxazines, Heterocyclic Compounds, 3-Ring, Piperazines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, Wellcome Trust.
Abstract (Originalsprache)
Aims
Dolutegravir increases serum creatinine by inhibiting its renal tubular secretion and elimination. We investigated determinants of early changes in serum creatinine in a southern African cohort starting first‐line dolutegravir‐based antiretroviral therapy (ART).
Methods
We conducted a secondary analysis of data from participants in a randomized controlled trial of dolutegravir, emtricitabine and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF) (ADVANCE, NCT03122262). We assessed clinical, pharmacokinetic and genetic factors associated with change in serum creatinine from baseline to Week 4 using linear regression models adjusted for age, sex, baseline serum creatinine, HIV‐1 RNA concentration, CD4 T‐cell count, total body weight and co‐trimoxazole use.
Results
We included 689 participants, of whom 470 had pharmacokinetic data and 315 had genetic data. Mean change in serum creatinine was 11.3 (SD 9.9) μmol.L −1 . Factors that were positively associated with change in serum creatinine at Week 4 were increased log dolutegravir area under the 24‐h concentration–time curve (change in creatinine coefficient [ β ] = 2.78 μmol.L −1 [95% confidence interval (CI) 0.54, 5.01]), TDF use ( β = 2.30 [0.53, 4.06]), male sex ( β = 5.20 [2.92, 7.48]), baseline serum creatinine ( β = −0.22 [−0.31, −0.12]) and UGT1A1 rs929596 A→G polymorphism with a dominant model ( β = −2.33 [−4.49, −0.17]). The latter did not withstand correction for multiple testing.
Conclusions
Multiple clinical and pharmacokinetic factors were associated with early change in serum creatinine in individuals initiating dolutegravir‐based ART. UGT1A1 polymorphisms may play a role, but further research on genetic determinants is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- King's College Hospital NHS Foundation Trust, London, UK.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee, USA.
- SAMRC/UCT Platform for Pharmacogenomics Research and Translation (PREMED) unit, Cape Town, South Africa.
ORCID-Profile: Rephaim Mpofu, Aida N Kawuma, Roeland E Wasmann, Godspower Akpomiemie, Nomathemba Chandiwana, Simiso Mandisa Sokhela, Michelle Moorhouse, Willem Daniel Francois Venter, Paolo Denti, Lubbe Wiesner, Frank A Post, David W Haas, Gary Maartens, Phumla Sinxadi
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
- Wellcome Trust
- NIAID NIH HHS
- FIC NIH HHS
- Wellcome Centre for Infectious Diseases Research in Africa
- Fogarty International Center
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Mpofu, R., Kawuma, A. N., Wasmann, R. E., Akpomiemie, G., Chandiwana, N., Sokhela, S. M., Moorhouse, M., Venter, W. D. F., Denti, P., Wiesner, L., Post, F. A., Haas, D. W., Maartens, G., & Sinxadi, P. (2024). Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa. British Journal of Clinical Pharmacology, 90(5), 1247-1257. https://doi.org/10.1111/bcp.16009
Vancouver
Mpofu R, Kawuma AN, Wasmann RE, Akpomiemie G, Chandiwana N, Sokhela SM, et al. Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa. British Journal of Clinical Pharmacology. 2024;90(5):1247-1257. doi:10.1111/bcp.16009
BibTeX
@article{Mpofu2024,
author = {Mpofu, Rephaim and Kawuma, Aida N and Wasmann, Roeland E and Akpomiemie, Godspower and Chandiwana, Nomathemba and Sokhela, Simiso Mandisa and Moorhouse, Michelle and Venter, Willem Daniel Francois and Denti, Paolo and Wiesner, Lubbe and Post, Frank A and Haas, David W and Maartens, Gary and Sinxadi, Phumla},
title = {Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {5},
pages = {1247--1257},
doi = {10.1111/bcp.16009}
}
EUVIMED